Skip to main content

TRS

Stock
Consumer Discretionary
Packaging & Containers

Performance overview

TRS Price
Price Chart

Forward-looking statistics

Beta
0.80
Risk
29.60%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

TriMas Corp is a United States-based company that designs, manufactures, and distributes engineered and applied products. The company operates through three segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The aerospace segment supplies blind bolts, fasteners, rivets, and other products for the aerospace industry. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners.

Company info

SectorConsumer Discretionary
IndustryPackaging & Containers
Employees2K
Market cap$1.1B

Fundamentals

Enterprise value
Revenue
Revenue per employee
Profit margin
Debt to equity

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)
Avg trading volume (10 day)
Put-call ratio

Macro factor sensitivity

Growth+0.6
Credit+4.6
Liquidity+0.9
Inflation-3.1
Commodities-0.5
Interest Rates-1.3

Valuation

Dividend yield0.00%
PEG Ratio
Price to sales
P/E Ratio12.59
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayApril 29, 2025
Next dividend day
Ex. dividend day

News

VTRS Down on Late-Stage Study Failure of Eye Disease Drug

VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.

Zacks Investment Research (July 21, 2025)
Seeking Clues to Northern Trust (NTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Get a deeper insight into the potential performance of Northern Trust (NTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Investment Research (July 21, 2025)
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. VTRS on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.

Benzinga (July 18, 2025)
Best Momentum Stock to Buy for July 10th

NTRS, STT and CADE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 10, 2025.

Zacks Investment Research (July 10, 2025)
TriMas (TRS) Up 10.2% Since Last Earnings Report: Can It Continue?

TriMas (TRS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (May 29, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free